Comparing Rotigotine patch to Neupro for Parkinson's
Part of Brain & nervous system clinical trials.
This trial tests whether a new rotigotine skin patch (Rotigexole) works as well and is as safe as the existing patch (Neupro). It is for people with Parkinson's who are in moderate stages and have not used similar dopamine agonist drugs recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 30 years old or older
- You have Parkinson's disease at stage II or III (moderate symptoms on both sides of the body, but still able to live independently)
- You have not used a dopamine agonist (like pramipexole or ropinirole) in the past 30 days, or you are willing to stop using it for the study
- You can think clearly (score at least 25 on a standard memory and thinking test)
- You can tolerate wearing the rotigotine patch for a 3-week gradual dose increase period
- You agree to avoid swimming, bathing, or sauna on assessment days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a skin patch called rotigotine to see if it is safe for people with ADPKD. It may help with blood pressure control, but you cannot have advanced kidney failure or certain other health issues.
This Phase 2 study tests whether a rotigotine skin patch, used alongside behavioral therapy, can help people reduce cocaine use. It also looks at changes in brain activity while you do study tasks.
This trial tests if adding a rotigotine patch to your usual rivastigmine treatment can help with symptoms of Alzheimer's. It is for people with mild to moderate Alzheimer's who have been stable on rivastigmine for at least 3 months.
This study tests an investigational drug to see if it can help people with early Parkinson's disease. It may offer a new treatment option to manage symptoms.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests a new tablet (VG081821AC) for people with early-to-mid-stage Parkinson's disease who have not recently used levodopa. The goal is to see if it can improve movement symptoms safely.
Hear when a new Idiopathic Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.